Utility of Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Early Stage Epithelial Ovarian Cancer

Comprehensive serum glycopeptide spectra analysis (CSGSA) evaluates >10,000 serum glycopeptides and identifies unique glycopeptide peaks and patterns via supervised orthogonal partial least-squares discriminant modeling. CSGSA was more accurate than cancer antigen 125 (CA125) or human epididymis...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Koji, Tanabe, Kazuhiro, Hayashi, Masaru, Ikeda, Masae, Yasaka, Miwa, Machida, Hiroko, Shida, Masako, Sato, Kenji, Yoshida, Hiroshi, Hirasawa, Takeshi, Imanishi, Tadashi, Mikami, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563232/
https://www.ncbi.nlm.nih.gov/pubmed/32825727
http://dx.doi.org/10.3390/cancers12092374
Descripción
Sumario:Comprehensive serum glycopeptide spectra analysis (CSGSA) evaluates >10,000 serum glycopeptides and identifies unique glycopeptide peaks and patterns via supervised orthogonal partial least-squares discriminant modeling. CSGSA was more accurate than cancer antigen 125 (CA125) or human epididymis protein 4 (HE4) for detecting early stage epithelial ovarian cancer. Combined CSGSA, CA125, and HE4 had improved diagnostic performance. Thus, CSGSA may be a useful screening tool for detecting early stage epithelial ovarian cancer.

Ejemplares similares